Beta-blockers (All routes except ocular) (versus unexposed) updated on 12-17-2024

Coarctation of aorta

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13901
R54398
Duan - Beta-blockers, 2017 Coarctation 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified 1.20 [0.30;4.30] 5/2,628   218/374,391 223 2,628
ref
S13888
R55952
Fisher - Beta-blockers (Controls unexposed, disease free), 2017 Coarctation of the aorta early pregnancy case control unexposed, disease free excluded Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified 2.61 [1.25;5.45]
excluded (control group)
9/49   -/- - 49
ref
S14244
R55964
Fisher - Beta-blockers (Controls unexposed, sick), 2017 Coarctation of the aorta early pregnancy case control unexposed, sick Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified 1.95 [0.88;4.32] 9/49   -/- - 49
ref
Total 2 studies 1.72 [0.87;3.40] 223 2,677
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Duan - Beta-blockers, 2017Duan - Beta-blockers, 2017 1.20[0.30; 4.30]2232,62826%ROB confusion: seriousROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: unclearROB reporting: NA Fisher - Beta-blockers (Controls unexposed, sick), 2017Fisher - Beta-blockers, 2017 1 1.95[0.88; 4.32]-4974%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 1.72[0.87; 3.40]2232,6770.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.20[0.32; 4.54]2232,628 -NADuan - Beta-blockers, 2017 1 case control studiescase control studies 1.95[0.88; 4.32]-49 -NAFisher - Beta-blockers (Controls unexposed, sick), 2017 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.20[0.32; 4.54]2232,628 -NADuan - Beta-blockers, 2017 1 unexposed, sickunexposed, sick 1.95[0.88; 4.32]-49 -NAFisher - Beta-blockers (Controls unexposed, sick), 2017 1 Tags Adjustment   - Yes  - Yes 1.72[0.87; 3.40]2232,6770%NADuan - Beta-blockers, 2017 Fisher - Beta-blockers (Controls unexposed, sick), 2017 2 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 1.72[0.87; 3.40]2232,6770%NADuan - Beta-blockers, 2017 Fisher - Beta-blockers (Controls unexposed, sick), 2017 2 All studiesAll studies 1.72[0.87; 3.40]2232,6770%NADuan - Beta-blockers, 2017 Fisher - Beta-blockers (Controls unexposed, sick), 2017 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 13888

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.17[1.14; 4.15]2232,6770%NADuan - Beta-blockers, 2017 Fisher - Beta-blockers (Controls unexposed, disease free), 2017 2 unexposed, sick controlsunexposed, sick controls 1.95[0.88; 4.32]-49 -NAFisher - Beta-blockers (Controls unexposed, sick), 2017 10.510.01.0